NCT05683834 2026-04-22Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative PersonsNational Institutes of Health Clinical Center (CC)Phase 1/2 Completed25 enrolled